Moreover, phase 2 clinical studies have demonstrated that intravenous administration of NPSP795 increased PTH concentrations in five ADH1 patients, and oral administration of encaleret increased plasma calcium and PTH without causing hypercalciuria in 13 ADH1 patients (18, 21). The gene discussed is ADH1A; the disease is Hypercalciuria.